Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to fight Hard-to-Treat liver cancers

NCT ID NCT05775159

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 25, 2026 · Updated 4 times

Summary

This phase 2 trial is testing several new immunotherapy drugs, alone or combined with standard chemotherapy, in people with advanced liver or bile duct cancer. The goal is to see if these combinations can shrink tumors or slow the disease. About 294 adults whose cancer has spread or cannot be removed by surgery will participate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Volrustomig, Rilvegostomig, Bevacizumab, Lenvatinib, Gemcitabine, Cisplatin
What this could lead to
If successful, this trial could point toward more effective treatment options for advanced liver and bile duct cancers, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early phase 2 trial with a small number of participants, so results may not apply to all patients. The drug combinations may cause significant side effects, and there is no guarantee of benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 294 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years at the time of signing the ICF. * Provision of a signed and dated written ICF. * Confirmed locally advanced or metastatic solid tumor specified in substudy based on histopathology. * Adequate organ and bone marrow function. * At least 1 measurable not previously irradiated lesion per RECIST 1.1 * Life expectancy of at least 12 weeks at the time of screening. * Willing and able to provide an adequate tumor sample. Exclusion Criteria: * History of allogeneic organ transplantation. * Active or prior documented autoimmune or inflammatory disorders. * Uncontrolled intercurrent illness. * History of another primary malignancy, leptomeningeal carcinomatosis, and active primary immunodeficiency. * Active infection, brain metastases or spinal cord compression. * Participants co-infected with HBV and hepatitis D virus (HDV). * Previous treatment in the present study. * For substudy 1, history of hepatic encephalopathy within 12 months prior to treatment allocation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biliary tract cancer Hepatocellular carcinoma

Contacts and locations

Locations

  • Research Site

    Birmingham, Alabama, 35233, United States

  • Research Site

    Los Angeles, California, 90089, United States

  • Research Site

    Orange, California, 92868, United States

  • Research Site

    Kansas City, Kansas, 66103, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Beijing, 100050, China

  • Research Site

    Beijing, 100142, China

  • Research Site

    Beijing, 101100, China

  • Research Site

    Chengdu, 610000, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chongqing, 400030, China

  • Research Site

    Fuzhou, 350007, China

  • Research Site

    Guangzhou, 510060, China

  • Research Site

    Guangzhou, 510515, China

  • Research Site

    Harbin, 150081, China

  • Research Site

    Nanning, 530021, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Hong Kong, 999077, Hong Kong

  • Research Site

    Shatin, 00000, Hong Kong

  • Research Site

    Florence, 50134, Italy

  • Research Site

    Milan, 20132, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Rozzano, 20089, Italy

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Kashiwa, 277-8577, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    Seongnam-si, 463-712, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Barcelona, 8035, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28040, Spain

  • Research Site

    Pamplona, 31008, Spain

  • Research Site

    Kaohsiung City, 80756, Taiwan

  • Research Site

    Kaohsiung City, 833, Taiwan

  • Research Site

    Taichung, 407219, Taiwan

  • Research Site

    Tainan, 70403, Taiwan

  • Research Site

    Tainan, 710, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Cambridge, CB2 0QQ, United Kingdom

  • Research Site

    London, NW3 2QG, United Kingdom

  • Research Site

    Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.